AI assistant
GlaxoSmithKline PLC — Director's Dealing 2017
Jul 17, 2017
5262_dirs_2017-07-17_dcce8018-f9b0-4707-8b01-467c54c4865c.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 2933L
GlaxoSmithKline PLC
17 July 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 70.538 (personal contribution) |
| £16.18 | 174.682 (personal contribution) |
| £16.18 | 190.188 (personal contribution) |
| £16.18 | 70.538(personal contribution) |
| £16.18 | 174.669 (personal contribution) |
| £16.18 | 190.176 (personal contribution) |
| £16.18 | 70.538 (matching shares) |
| £16.18 | 174.682 (matching shares) |
| £16.18 | 190.188 (matching shares) |
| £16.18 | 70.538 (matching shares) |
| £16.18 | 174.669 (matching shares) |
| £16.18 | 190.176 (matching shares) |
d)
Aggregated information
Aggregated volume Price
1,741.582
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 51.658 (personal contribution) |
| £16.18 | 118.682 (personal contribution) |
| £16.18 | 99.029 (personal contribution) |
| £16.18 | 51.658 (personal contribution) |
| £16.18 | 99.017 (personal contribution) |
| £16.18 | 51.658 (matching shares) |
| £16.18 | 118.682 (matching shares) |
| £16.18 | 99.029 (matching shares) |
| £16.18 | 51.658 (matching shares) |
| £16.18 | 99.017 (matching contribution) |
d)
Aggregated information
Aggregated volume Price
840.088
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 166.446 (personal contribution) |
| £16.18 | 166.433 (personal contribution) |
| £16.18 | 166.446 (matching shares) |
| £16.18 | 166.433 (matching shares) |
d)
Aggregated information
Aggregated volume Price
665.758
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 98.527 (personal contribution) |
| £16.18 | 230.682 (personal contribution) |
| £16.18 | 172.780 personal contribution) |
| £16.18 | 98.514 (personal contribution) |
| £16.18 | 230.669 (personal contribution) |
| £16.18 | 172.780 (personal contribution) |
| £16.18 | 98.527 (matching shares) |
| £16.18 | 230.682 (matching shares) |
| £16.18 | 172.780 (matching shares) |
| £16.18 | 98.514 (matching shares) |
| £16.18 | 230.669 (matching shares) |
| £16.18 | 172.780 (matching shares) |
d)
Aggregated information
Aggregated volume Price
2,007.904
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 36.169 (personal contribution) |
| £16.18 | 85.292 (personal contribution) |
| £16.18 | 62.593 (personal contribution) |
| £16.18 | 36.169 (personal contribution) |
| £16.18 | 85.292 (personal contribution) |
| £16.18 | 62.582 (personal contribution) |
| £16.18 | 36.169 (matching shares) |
| £16.18 | 85.292 (matching shares) |
| £16.18 | 62.593 (matching shares) |
| £16.18 | 36.169 (matching shares) |
| £16.18 | 85.292 (matching shares) |
| £16.18 | 62.582 (matching shares) |
d)
Aggregated information
Aggregated volume Price
736.194
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S A Hussain
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 170.501 (personal contribution) |
| £16.18 | 201.553 (personal contribution) |
| £16.18 | 173.006 personal contribution) |
| £16.18 | 201.553 (personal contribution) |
| £16.18 | 172.994 (personal contribution) |
| £16.18 | 170.501 (matching shares) |
| £16.18 | 201.553 (matching shares) |
| £16.18 | 173.006 (matching shares) |
| £16.18 | 201.553 (matching shares) |
| £16.18 | 172.994 (matching shares) |
d)
Aggregated information
Aggregated volume Price
1,839.214
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $42.50 | 70.929 (personal contribution) |
| $42.50 | 70.929 (matching shares) |
d)
Aggregated information
Aggregated volume Price
141.858
$42.50
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 57.960 (personal contribution) |
| £16.18 | 108.550 (personal contribution) |
| £16.18 | 78.775 (personal contribution) |
| £16.18 | 57.960 (personal contribution) |
| £16.18 | 108.550 (personal contribution) |
| £16.18 | 78.763 (personal contribution) |
| £16.18 | 57.960 (matching shares) |
| £16.18 | 108.550 (matching shares) |
| £16.18 | 78.775 (matching shares) |
| £16.18 | 57.960 (matching shares) |
| £16.18 | 108.550 (matching shares) |
| £16.18 | 78.763 (matching shares) |
d)
Aggregated information
Aggregated volume Price
981.116
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 78.015 (personal contribution) |
| £16.18 | 158.805 (personal contribution) |
| £16.18 | 118.568 (personal contribution) |
| £16.18 | 78.002 (personal contribution) |
| £16.18 | 158.805 (personal contribution) |
| £16.18 | 118.568 (personal contribution) |
| £16.18 | 78.015 (matching shares) |
| £16.18 | 158.805 (matching shares) |
| £16.18 | 118.568 (matching shares) |
| £16.18 | 78.002 (matching shares) |
| £16.18 | 158.805 (matching shares) |
| £16.18 | 118.568 (matching shares) |
d)
Aggregated information
Aggregated volume Price
1,421.526
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 52.988 (personal contribution) |
| £16.18 | 97.162 (personal contribution) |
| £16.18 | 74.644 (personal contribution) |
| £16.18 | 52.988 (matching shares) |
| £16.18 | 97.162 (matching shares) |
| £16.18 | 74.644 matching shares) |
d)
Aggregated information
Aggregated volume Price
449.588
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $42.50 | 40.363 (personal contribution) |
| $42.50 | 90.880 (personal contribution) |
| $42.50 | 75.270 (personal contribution) |
| $42.50 | 40.363 (personal contribution) |
| $42.50 | 90.880 (personal contribution) |
| $42.50 | 75.258 (personal contribution) |
| $42.50 | 40.363 (matching shares) |
| $42.50 | 90.880 (matching shares) |
| $42.50 | 75.270 (matching shares) |
| $42.50 | 40.363 (matching shares) |
| $42.50 | 90.880 (matching shares) |
| $42.50 | 75.258 (matching shares) |
d)
Aggregated information
Aggregated volume Price
826.028
$42.50
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.18 | 114.838 (personal contribution) |
| £16.18 | 186.805 (personal contribution) |
| £16.18 | 128.784 (personal contribution) |
| £16.18 | 114.838 (personal contribution) |
| £16.18 | 186.805 (personal contribution) |
| £16.18 | 128.784 (personal contribution) |
| £16.18 | 114.838 (matching shares) |
| £16.18 | 186.805 (matching shares) |
| £16.18 | 128.784 (matching shares) |
| £16.18 | 114.838 (matching shares) |
| £16.18 | 186.805 (matching shares) |
| £16.18 | 128.784 (matching shares) |
d)
Aggregated information
Aggregated volume Price
1,721.708
£16.18
e)
Date of the transaction
2017-07-14
f)
Place of the transaction
n/a
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEDLFFDDFXBBE